BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 19614947)

  • 1. Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus.
    Kawamori R; Kadowaki T; Ishii H; Iwasaki M; Iwamoto Y
    Diabetes Obes Metab; 2009 Sep; 11(9):891-9. PubMed ID: 19614947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus.
    Kawamori R; Iwamoto Y; Kadowaki T; Iwasaki M; Kim SW; Woo JT; Baik SH; Yoon KH
    Diabetes Obes Metab; 2009 Sep; 11(9):900-9. PubMed ID: 19614946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.
    Ashwell SG; Amiel SA; Bilous RW; Dashora U; Heller SR; Hepburn DA; Shutler SD; Stephens JW; Home PD
    Diabet Med; 2006 Mar; 23(3):285-92. PubMed ID: 16492212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P; Malone JK
    Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
    Porcellati F; Rossetti P; Pampanelli S; Fanelli CG; Torlone E; Scionti L; Perriello G; Bolli GB
    Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes.
    Philotheou A; Arslanian S; Blatniczky L; Peterkova V; Souhami E; Danne T
    Diabetes Technol Ther; 2011 Mar; 13(3):327-34. PubMed ID: 21291333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy.
    Kazda C; Hülstrunk H; Helsberg K; Langer F; Forst T; Hanefeld M
    J Diabetes Complications; 2006; 20(3):145-52. PubMed ID: 16632233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
    Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes.
    Bramlage P; Tittel SR; Müther S; Reinhart-Steininger B; Haberland H; Khodaverdi S; Zimny S; Ohlenschläger U; Lanzinger S; Haak T
    Acta Diabetol; 2022 Nov; 59(11):1453-1460. PubMed ID: 35933650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
    Koivisto V; Cleall S; Pontiroli AE; Giugliano D
    Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.
    Arakaki RF; Blevins TC; Wise JK; Liljenquist DR; Jiang HH; Jacobson JG; Martin SA; Jackson JA
    Diabetes Obes Metab; 2014 Jun; 16(6):510-8. PubMed ID: 24298995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study.
    Fritsche A; Larbig M; Owens D; Häring HU;
    Diabetes Obes Metab; 2010 Feb; 12(2):115-23. PubMed ID: 20092584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
    Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
    Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.